scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC raised its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 84.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 778,874 shares of the company’s stock after acquiring an additional 357,171 shares during the period. scPharmaceuticals makes up approximately 2.2% of Stonepine Capital Management LLC’s holdings, making the stock its 15th biggest holding. Stonepine Capital Management LLC owned 1.56% of scPharmaceuticals worth $3,552,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in scPharmaceuticals in the second quarter valued at approximately $1,544,000. King Luther Capital Management Corp raised its holdings in shares of scPharmaceuticals by 51.8% in the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after buying an additional 752,005 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of scPharmaceuticals by 76.9% in the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock worth $2,163,000 after buying an additional 216,122 shares during the last quarter. AIGH Capital Management LLC raised its holdings in shares of scPharmaceuticals by 3.4% in the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock worth $15,244,000 after buying an additional 115,206 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of scPharmaceuticals by 266.7% in the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after buying an additional 52,870 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors and hedge funds.

scPharmaceuticals Stock Performance

Shares of scPharmaceuticals stock traded up $0.05 during trading on Wednesday, hitting $3.65. 31,650 shares of the company’s stock were exchanged, compared to its average volume of 273,608. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The business has a 50-day simple moving average of $4.20 and a 200-day simple moving average of $4.42. scPharmaceuticals Inc. has a 52-week low of $3.08 and a 52-week high of $6.71. The stock has a market capitalization of $182.65 million, a price-to-earnings ratio of -1.89 and a beta of 0.15.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Craig Hallum decreased their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, November 14th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.